{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:10:38Z","timestamp":1786997438589,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.therap.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T12:12:17Z","timestamp":1599048737000},"page":"467-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases"],"prefix":"10.1016","volume":"76","author":[{"given":"Alia","family":"Fazaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Makhlouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amad","family":"Ben Ouhiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saoussen","family":"Miladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Sellami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kmar","family":"Ouenniche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Souabni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Kassab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Chekili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leith","family":"Zakraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawther","family":"Ben Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Laatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.therap.2020.08.003_bib0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5114\/reum.2019.89515","article-title":"New era of treatment with biologics in rheumatology\u00a0\u2013\u00a0is it time to shift paradigms in treatment with biologics?","volume":"57","author":"Felis-Giemza","year":"2019","journal-title":"Reumatologia"},{"issue":"22","key":"10.1016\/j.therap.2020.08.003_bib0155","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.3390\/ijms20225552","article-title":"Wnt signaling and biological therapy in rheumatoid arthritis and spondyloarthritis","volume":"20","author":"Cici","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"10.1016\/j.therap.2020.08.003_bib0160","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012","volume":"72","author":"Furst","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.08.003_bib0165","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.08.003_bib0170","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.therap.2020.08.003_bib0175","first-page":"2469","article-title":"The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study","volume":"30","author":"De Klerk","year":"2003","journal-title":"J Rheumatol"},{"issue":"21","key":"10.1016\/j.therap.2020.08.003_bib0180","first-page":"1044","article-title":"Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic","volume":"30","author":"Girerd","year":"2001","journal-title":"Presse Med"},{"issue":"12","key":"10.1016\/j.therap.2020.08.003_bib0185","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2147\/PPA.S167508","article-title":"Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review","volume":"21","author":"Murage","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"10.1016\/j.therap.2020.08.003_bib0190","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00296-017-3758-6","article-title":"Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study","volume":"37","author":"Mena-Vazquez","year":"2017","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.therap.2020.08.003_bib0195","first-page":"915","article-title":"Adherence in rheumatoid arthritis patients assessed with a validated Italian version of the 5-item compliance questionnaire for rheumatology","volume":"37","author":"Ometto","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.therap.2020.08.003_bib0200","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00296-006-0299-9","article-title":"Factors affecting drug treatment compliance in patients with rheumatoid arthritis","volume":"27","author":"Tuncay","year":"2017","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.therap.2020.08.003_bib0205","first-page":"1421","article-title":"RA: only 1 in 5 patients take oral meds as prescribed","volume":"65","author":"Kelly Janis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.therap.2020.08.003_bib0210","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00296-017-3737-y","article-title":"Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study","volume":"37","author":"Marras","year":"2017","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.therap.2020.08.003_bib0215","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/acr.20087","article-title":"Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission","volume":"62","author":"Grijalva","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.therap.2020.08.003_bib0220","first-page":"657","article-title":"Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis","volume":"20","author":"Oladapo","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.therap.2020.08.003_bib0225","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10067-013-2221-7","article-title":"Adherence to treatment in patients with ankylosing spondylitis","volume":"32","author":"Arturi","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.therap.2020.08.003_bib0230","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12325-015-0256-7","article-title":"A systematic review of factors associated with non-adhrence to treatment for immune-medicated inflammatory diseases","volume":"32","author":"Vangeli","year":"2015","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.therap.2020.08.003_bib0235","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/art.24114","article-title":"Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?","volume":"59","author":"Curkendall","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.therap.2020.08.003_bib0240","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1524-4733.2010.00764.x","article-title":"Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis","volume":"13","author":"Li","year":"2010","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.therap.2020.08.003_bib0245","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.clinthera.2014.02.019","article-title":"Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients","volume":"36","author":"Tkacz","year":"2014","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.therap.2020.08.003_bib0250","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clinthera.2014.10.022","article-title":"Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients","volume":"37","author":"Chu","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.therap.2020.08.003_bib0255","series-title":"Adh\u00e9sion m\u00e9dicamenteuse et repr\u00e9sentations des patients atteints de rhumatisme inflammatoire chronique sous bioth\u00e9rapie [Th\u00e8se]","author":"Betegnie","year":"2013"},{"issue":"2","key":"10.1016\/j.therap.2020.08.003_bib0260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/MAJ.0000000000000376","article-title":"Assessment of rheumatoid arthritis patients\u2019 adherence to treatment","volume":"349","author":"Gadallah","year":"2015","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.therap.2020.08.003_bib0265","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.therap.2020.08.003_bib0270","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1185\/03007990902896386","article-title":"Trends in RA patients\u2019 adherence to subcutaneous anti-TNF therapies and costs","volume":"25","author":"Borah","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.therap.2020.08.003_bib0275","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1517\/14712598.2010.510508","article-title":"Adherence to biologic DMARD therapies in rheumatoid arthritis","volume":"10","author":"Koncz","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.therap.2020.08.003_bib0280","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/ar2084","article-title":"Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden","volume":"8","author":"Kristensen","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.therap.2020.08.003_bib0285","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/acr.22638","article-title":"Etanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis","volume":"67","author":"Bonafede","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"10 Suppl 2","key":"10.1016\/j.therap.2020.08.003_bib0290","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/MLR.0b013e318041384c","article-title":"Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis","volume":"45","author":"Grijalva","year":"2007","journal-title":"Med Care"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:58Z","timestamp":1758567298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720301499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0040595720301499"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.08.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}